Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + carboplatin + erlotinib + pemetrexed
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A four-drug combination therapy consisting of bevacizumab (an anti-vascular endothelial growth factor antibody), carboplatin (a platinum-based chemotherapy agent), erlotinib (an epidermal growth factor receptor tyrosine kinase inhibitor), and pemetrexed (an antifolate antineoplastic agent). This regimen has been studied primarily for the treatment of advanced non-squamous non-small cell lung cancer (NSCLC), particularly in patients with EGFR mutations. The combination aims to target multiple cancer pathways simultaneously, including angiogenesis, DNA replication, EGFR signaling, and folate metabolism.
02
Targets
TS (Thymidylate synthase)DHFR (Dihydrofolate reductase)VEGFA (Vascular endothelial growth factor A)DNAEGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on bevacizumab + carboplatin + erlotinib + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + carboplatin + erlotinib + pemetrexed.